Esperion therapeutics, inc. (ESPR)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12
Revenues:
Total Revenues

4,822

148,401

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses:
Cost of goods sold

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

164,005

175,611

186,850

180,120

176,856

171,488

155,454

153,959

152,683

147,603

139,045

112,487

83,937

57,868

40,943

34,692

32,203

29,802

28,046

27,973

27,292

25,302

26,440

22,749

19,321

16,014

10,330

9,303

8,533

7,998

0

0

0

Selling, general and administrative

95,225

65,854

55,318

45,861

39,325

33,097

27,178

23,848

22,304

21,379

20,526

19,059

18,280

18,282

19,156

20,614

21,234

20,238

18,140

14,994

12,467

10,922

10,140

9,538

7,984

6,745

4,852

3,462

2,824

2,205

0

0

0

Total operating expenses

259,261

241,465

242,168

225,981

216,181

204,585

182,632

177,807

174,987

168,982

159,571

131,546

102,217

76,150

60,099

55,306

53,437

50,040

46,186

42,967

39,759

36,224

36,580

32,287

27,305

22,759

15,183

12,766

11,358

10,203

0

0

0

Income (loss) from operations

-254,476

-93,101

-94,786

-79,580

-70,762

-204,585

-182,632

-177,807

-174,987

-168,982

-159,571

-131,546

-102,217

-76,150

-60,099

-55,306

-53,437

-50,040

-46,186

-42,967

-39,759

-36,224

-36,580

-32,287

-27,305

-22,759

-15,183

-12,766

-11,358

-10,203

0

0

0

Interest expense

0

0

0

-

-

-

-

-

-

-

-

-

-

376

419

460

496

520

533

538

404

0

0

0

-

936

1,497

1,859

2,054

1,486

0

0

0

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,587

2,554

0

0

0

-

-

-

Other income, net

3,974

4,056

3,524

2,788

2,461

2,775

2,970

2,837

2,410

1,994

1,596

1,477

1,549

1,548

1,374

1,223

1,030

776

600

381

196

119

108

248

235

194

61

-106

-109

-83

0

0

0

Net income (loss)

-262,793

-97,165

-95,258

-76,792

-68,301

-201,810

-179,662

-174,970

-172,577

-166,988

-158,053

-130,236

-100,934

-74,978

-59,144

-54,543

-52,903

-49,784

-46,119

-43,124

-39,967

-36,375

-36,608

-32,040

-29,723

-26,088

-19,173

-17,286

-13,531

-11,741

0

0

0

Net income (loss) per common share - basic

-2.84

-

-

-2.01

3.26

-

-

-1.71

-1.73

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net income (loss) per common share - diluted

-2.84

-

-

-2.01

3.07

-

-

-1.71

-1.73

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted-average shares outstanding - basic

27,519

-

-

26,968

26,842

-

-

26,786

26,605

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted-average shares outstanding - diluted

27,519

-

-

26,968

28,449

-

-

26,786

26,605

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss per common share (basic and diluted)

-

-

-2.52

-

-

-2.24

-1.86

-

-

-1.44

-1.86

-1.92

-1.80

-1.29

-0.77

-0.62

-0.65

-0.58

-0.57

-0.55

-0.56

-0.49

-0.64

-0.60

-0.51

29.09

-0.34

-19.82

-12.24

-8.12

-10.31

-9.94

-7.96

Weighted-average shares outstanding (basic and diluted)

-

-

27,171

-

-

26,818

26,804

-

-

26,222

24,311

22,591

22,563

22,554

22,550

22,541

22,532

22,515

22,494

22,465

20,589

19,276

15,432

15,399

15,369

15,594

15,253

349

346

341

325

318

307

Other comprehensive income (loss):
Unrealized gain (loss) on investments

120

342

571

760

852

526

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-56

4

0

0

-

0

-

-

-

-

-

-

Comprehensive income (loss)

-262,673

-96,823

-94,687

-76,032

-67,449

-201,284

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-36,431

-32,152

0

0

-

0

-

-

-

-

-

-

Product sales, net
Total Revenues

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration revenue
Total Revenues

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-